Sanofi India Limited

SANOFI

INE058A01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-29 am EDT			5-day change	1st Jan Change
8,282 ^INR	+0.05%		+0.71%	+2.66%

Apr. 15	Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility	CI
Mar. 28	Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee	CI

Sanofi India Limited Announces Resignation of Gaurav Bahadur as People Director

August 03, 2023 at 03:43 am EDT

Sanofi India Limited announced that Mr. Gaurav Bahadur, India People Director, resigned from the Company with effect from the close of business hours on 1st August, 2023, to pursue other opportunities outside Sanofi. As a result, he shall also cease to be a Senior Management Personnel of the Company.

Latest news about Sanofi India Limited

Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility	Apr. 14	CI
Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee	Mar. 28	CI
Cipla to Distribute Sanofi's CNS Product Line in India	Mar. 26	MT
Sanofi India Limited, Sanofi Healthcare India Private Limited and Cipla Limited Announce an Exclusive Partnership	Mar. 26	CI
Sanofi India Limited and Emcure Pharmaceuticals Announces Exclusive Distribution Partnership to Broad Broadline Reach of Sanofi's Cardiovascular Brands	Mar. 13	CI
Transcript : Sanofi India Limited, Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024	Feb. 23	CI
Sanofi India Limited Declares Interim Dividend for the Financial Year Ended 31St December, 2023, Payable on or After 20 March, 2024	Feb. 23	CI
Sanofi India Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Sanofi India Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 23	CI
Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024	Jan. 10	CI
Sanofi Sees Improvement in Trial Results of Cancer Drug Sarclisa	Dec. 11	DJ
Trending : Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials	Dec. 06	DJ
Transcript : Sanofi India Limited, Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
Sanofi India's CFO Steps Down	Nov. 08	MT
Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director	Nov. 08	CI
Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Chief Financial Officer, effective November 30, 2023	Nov. 08	CI
Sanofi India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Sanofi India Limited Appoints Surabhi Kaul as India People Director and Will Be Part of the Senior Management Personnel	23-10-17	CI
Sanofi India Limited Announces Executive Changes	23-09-26	CI
Sanofi India Limited Announces Resignation of Vinita Korti Patil as Senior Legal Director - South Asia, Effective 7 December 2023	23-09-14	CI
Sanofi India Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Sanofi India Limited Announces Resignation of Gaurav Bahadur as People Director	23-08-03	CI
Sanofi India Limited Announces Resignation of Annapurna Das as Non-Executive Director and Member of the Audit Committee, Effective 31 July 2023	23-07-20	CI
Sanofi India's Consolidated Profit Declines in Fiscal Q4; Shares Jump 8%	23-05-11	MT

Chart Sanofi India Limited

Duration

Period

More charts

Company Profile

Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sanofi India Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SANOFI INDIA LIMITED	+2.66%	2.29B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.81%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+11.57%	14.09B
CIPLA LIMITED	+12.97%	13.64B
ZYDUS LIFESCIENCES LIMITED	+39.74%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals